Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi
Abroad (travel likely)RecruitingPHASE2
Conditions
Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Contact: Principal Investigator (Kerry A. Rogers)
Study leads
Kerry A Rogers, MD
Principal Investigator
Ohio State University Comprehensive Cancer Center